European Regulators Show Mixed Support for Lilly’s Alzheimer’s Treatments
TL;DR
The EMA's CHMP recommended approval for 13 new medicines in July 2025, including treatments for rare diseases, cancer, HIV prevention, and postpartum depression, along with biosimilars, generics, and updates on vaccine compositions. Several applications were withdrawn or received negative opinions, while some medicines underwent re-examination or extension of indications. The meeting also included safety reviews and updates on ongoing public health procedures.
- Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 July 2025 European Medicines Agency
- Donanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimer's disease Eli Lilly and Company
- Lilly Gets Limited European Backing for Alzheimer’s Drug Bloomberg
- EMA Poised To Decide On Fate Of Lilly’s Kisunla And PharmaMar’s Aplidin In EU insights.citeline.com
- European regulators endorse Lilly���s Alzheimer’s treatment for certain patients statnews.com
Want the full story? Read the original reporting
Read on European Medicines Agency